Aug 2026· Vaccine· Vol 90, pp.
129030
· 0 citations· 18 references
Medicine
TL;DR
It was found that, during a 5-month study period with low incidence, JN.1-vaccination provided limited added protection in preventing SARS-CoV-2 infection.
Abstract
INTRODUCTION
We estimated vaccine effectiveness (VE) of JN.1 COVID-19 vaccination against SARS-CoV-2 infection by (sub)variant between 23 September 2024 and 23 February 2025.
Methods
JN.1 vaccine-eligible participants of an ongoing prospective cohort study (VAccine Study COvid-19; VASCO) were included: individuals aged ≥60 years, and individuals aged <60 years with a medical risk condition or who were healthcare workers. In VASCO, questionnaire and serology data are regularly collected and self-tests are provided. SARS-CoV-2 infection was based on reported positive self-tests and/or anti-nucleoprotein serology results. The variant of infection was determined by whole genome sequencing of viral genetic material in positive self-tests. VE against infection was estimated using Cox regression with JN.1-vaccination as time-varying exposure, and VE against JN.1 subvariants KP.3.1.1 and XEC using multinomial logistic regression with matching of infected and uninfected participants by calendar week. Models were adjusted for age group, sex, education level, medical risk condition and SARS-CoV-2 infection history.
Results
Of 4490 JN.1-vaccine eligible participants <60 years, 1283 (29%) were vaccinated. Of 19,349 participants ≥60 years, 14,400 (74%) were vaccinated. During follow-up 2142 infections occurred, of which the majority was self-reported (72%). VE was 16% (95%CI: -11-36) in participants <60 years and 13% (95%CI: 2-23) in participants ≥60 years. VE against KP.3.1.1 (n = 251;27%) did not differ significantly from the VE against XEC (n = 195;5%)(OR:1.3; 0.8-2.1).
Conclusion
We found that, during a 5-month study period with low incidence, JN.1-vaccination provided limited added protection in preventing SARS-CoV-2 infection. The observed VE estimates indicate potentially lower protection against XEC than KP.3.1.1, but the power to detect such a difference was low.
COVID-19 immune responses differ between children and adults, with adolescents exhibiting stronger immune response to vaccination than children younger than 12, however vaccine dosage may play a role in this observed difference.
Brooke A. Hawkes, J. Hollister, Cynthia Porter et al.· PLoS ONE· 0 citations
These findings provide rare data on variant-specific vaccine-elicited antibody binding responses in West and Central African populations with distinct demographic, epidemiologic, and immunologic background.
E. Lusamaki, Ana M. Ortega-Villa, Daouda Camara et al.· Scientific Reports· 0 citations
SARS-CoV-2 infection induces neutralizing antibodies (nAbs) which are essential for clearing the virus and protecting against severe disease. We aimed to compare nAb titers between vaccinated and non-vaccinated subjects and evaluate factors associated with nAb responses. A total of 194 individuals recovered from SARS-C...
Gurdeep Singh, M. Chaudhry, M. Ali et al.· Discover Public Health· 0 citations
A pronounced HVE was observed for SARS-CoV-2 vaccination during the pandemic, evidenced by markedly lower mortality from causes not plausibly related to vaccination (cancer, external causes) among vaccinated individuals.
U. Riedmann, H. Brenner, J. Ioannidis et al.· medRxiv· 0 citations
Early after household exposure, binding and neutralising antibodies were similar in all participants, but differences in T-cell functional responses were evident in individuals who developed symptoms after SARS-CoV-2 infection.
Christopher Kandel, Jessica A. Breznik, Maureen Taylor et al.· The Lancet Microbe· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.